Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 10 » Issue 1

The chronic obstructive pulmonary disease assessment test improves the predictive value of previous exacerbations for poor outcomes in COPD

Authors Miravitlles M, García-Sidro P, Fernández-Nistal A, Buendía MJ, Espinosa de los Monteros MJ, Esquinas C, Molina J

Received 25 June 2015

Accepted for publication 14 September 2015

Published 30 November 2015 Volume 2015:10(1) Pages 2571—2579

DOI https://doi.org/10.2147/COPD.S91163

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Professor Hsiao-Chi Chuang

Peer reviewer comments 4

Editor who approved publication: Dr Richard Russell

Marc Miravitlles,1 Patricia García-Sidro,2 Alonso Fernández-Nistal,3 María Jesús Buendía,4 María José Espinosa de los Monteros,5 Cristina Esquinas,1 Jesús Molina6

1Pneumology Department, Hospital Universitari Vall d’Hebron, Ciber de Enfermedades Respiratorias, Barcelona, 2Pneumology Unit, Hospital de la Plana, Villareal, 3Medical Department, Takeda Farmacéutica España S.A., Madrid, 4Pneumology Department, Hospital Universitario Infanta Leonor, Madrid, 5Pneumology Department, Hospital Universitario Virgen de la Salud, Toledo, 6Centro de Salud “Francia”, Fuenlabrada, Madrid, Spain


Introduction: Chronic obstructive pulmonary disease (COPD) exacerbations have a negative impact on the quality of life of patients and the evolution of the disease. We have investigated the prognostic value of several health-related quality of life questionnaires to predict the appearance of a composite event (new ambulatory or emergency exacerbation, hospitalization, or death) over a 1-year follow-up.
Methods: This was a multicenter, prospective, observational study. Patients completed four questionnaires after recovering from an exacerbation (COPD Assessment Test [CAT], a Clinical COPD Questionnaire [CCQ], COPD Severity Score [COPDSS], and Airways Questionnaire [AQ20]). Patients were followed-up until the appearance of the composite event or for 1 year, whichever came first.
Results: A total of 497 patients were included in the study. The majority of them were men (89.7%), with a mean age of 68.7 (SD 9.2) years, and a forced expiratory volume in 1 second of 47.1% (SD 17.5%). A total of 303 (61%) patients experienced a composite event. Patients with an event had worse mean scores of all questionnaires at baseline compared to patients without event: CAT=12.5 vs 11.3 (P=0.028); CCQ=2.2 vs 1.9 (P=0.013); COPDSS=12.3 vs 10.9 (P=0.001); AQ20=8.3 vs 7.5 (P=0.048). In the multivariate analysis, only previous history of exacerbations and CAT score ≥13.5 were significant risk factors for the composite event. A CAT score ≥13.5 increased the predictive value of previous exacerbations with an area under the receiver operating characteristic curve of 0.864 (95% CI: 0.829–0.899; P=0.001).
Conclusion: The predictive value of previous exacerbations significantly increased only in one of the four trialled questionnaires, namely in the CAT questionnaire. However, previous history of exacerbations was the strongest predictor of the composite event.

Keywords: COPD, CAT, CCQ, COPDSS, AQ20, exacerbations

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Palliative care and prognosis in COPD: a systematic review with a validation cohort

Almagro P, Yun S, Sangil A, Rodríguez-Carballeira M, Marine M, Landete P, Soler-Cataluña JJ, Soriano JB, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1721-1729

Published Date: 9 June 2017

Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide

Blanco I, Bueno P, Diego I, Pérez-Holanda S, Lara B, Casas-Maldonado F, Esquinas C, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1683-1694

Published Date: 8 June 2017

Bronchiectasis in COPD patients: more than a comorbidity?

Martinez-Garcia MA, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1401-1411

Published Date: 11 May 2017

Self-reported daily walking time in COPD: relationship with relevant clinical and functional characteristics

Ramon MA, Esquinas C, Barrecheguren M, Pleguezuelos E, Molina J, Quintano JA, Roman-Rodríguez M, Naberan K, Llor C, Roncero C, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1173-1181

Published Date: 13 April 2017

Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update

Blanco I, Bueno P, Diego I, Pérez-Holanda S, Casas-Maldonado F, Esquinas C, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:561-569

Published Date: 13 February 2017

Diagnosis of alpha-1 antitrypsin deficiency: a population-based study

Barrecheguren M, Monteagudo M, Simonet P, Llor C, Rodriguez E, Ferrer J, Esquinas C, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:999-1004

Published Date: 10 May 2016

A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD

Miravitlles M, Montero-Caballero J, Richard F, Santos S, Garcia-Rivero JL, Ortega F, Ribera X

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:407-415

Published Date: 26 February 2016

Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients

Miravitlles M, Gáldiz JB, Huerta A, Villacampa A, Carcedo D, Garcia-Rio F

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:123-132

Published Date: 18 January 2016

Is a previous diagnosis of asthma a reliable criterion for asthma–COPD overlap syndrome in a patient with COPD?

Barrecheguren M, Román-Rodríguez M, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1745-1752

Published Date: 1 September 2015

What pulmonologists think about the asthma–COPD overlap syndrome

Miravitlles M, Alcázar B, Alvarez FJ, Bazús T, Calle M, Casanova C, Cisneros C, de-Torres JP, Entrenas LM, Esteban C, García-Sidro P, Cosio BG, Huerta A, Iriberri M, Izquierdo JL, López-Viña A, López-Campos JL, Martínez-Moragón E, Pérez de Llano L, Perpiñá M, Ros JA, Serrano J, Soler-Cataluña JJ, Torrego A, Urrutia I, Plaza V

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1321-1330

Published Date: 15 July 2015

Clinical variables impacting on the estimation of utilities in chronic obstructive pulmonary disease

Miravitlles M, Huerta A, Valle M, García-Sidro P, Forné C, Crespo C, López-Campos JL

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:367-377

Published Date: 16 February 2015

Caregivers’ burden in patients with COPD

Miravitlles M, Peña-Longobardo LM, Oliva-Moreno J, Hidalgo-Vega Á

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:347-356

Published Date: 12 February 2015

The concept of control of COPD in clinical practice

Soler-Cataluña JJ, Alcázar-Navarrete B, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1397-1405

Published Date: 12 December 2014

Geographic differences in clinical characteristics and management of COPD: the EPOCA study

Marc Miravitlles, Cristina Murio, Gema Tirado-Conde, Gur Levy, Hana Muellerova, et al

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:803-814

Published Date: 5 December 2008

Readers of this article also read:

The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients

Darbà J, Ramírez G, Sicras A, Francoli P, Torvinen S, Sánchez-de la Rosa R

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2335-2345

Published Date: 29 October 2015

The phenotype of concurrent chronic bronchitis and frequent exacerbations in patients with severe COPD attending Swedish secondary care units

Sundh J, Johansson G, Larsson K, Lindén A, Löfdahl CG, Sandström T, Janson C

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2327-2334

Published Date: 28 October 2015

Glutathione-degradable drug-loaded nanogel effectively and securely suppresses hepatoma in mouse model

Liu XG, Wang JM, Xu WG, Ding JX, Shi B, Huang KX, Zhuang XL, Chen XS

International Journal of Nanomedicine 2015, 10:6587-6602

Published Date: 22 October 2015

Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system

Wang H, Liu J, Tao S, Chai GH, Wang JW, Hu FQ, Yuan H

International Journal of Nanomedicine 2015, 10:5671-5685

Published Date: 8 September 2015

Roflumilast in COPD: a Brazilian perspective

Stirbulov R, Jardim JR

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1853-1855

Published Date: 8 September 2015

Epidemiology of chronic obstructive pulmonary disease: a population-based study in Krasnoyarsk region, Russia

Artyukhov IP, Arshukova IL, Dobretsova EA, Dugina TA, Shulmin AV, Demko IV

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1781-1786

Published Date: 2 September 2015